Retatrutide: What the Phase 3 Results Showed — and Why You Can’t Get It Yet

By Dr. Don Gates, MD, Founder of Scale Solutions

Retatrutide is an investigational medication. It is not FDA approved, no physician can legally prescribe it, and it cannot be legally compounded by any pharmacy in the United States. Its Phase 3 results are also the strongest weight-reduction data yet reported for an obesity medication — an average of 28.3% of body weight lost at 80 weeks on the highest dose.

Both of those things are true at once, and holding them together is the whole point of this article. The data is real. The drug is not available. And the gap between those two facts is being filled by websites selling vials labeled “for research use only.”

FDA status, trial data, and regulatory information verified as of August 19, 2026.

Key Takeaways

• Retatrutide is not FDA approved and is not available by prescription. Its manufacturer has stated it plans to submit an application to the FDA in the first quarter of 2027. Submission is the start of the review process, not the end.
• The Phase 3 TRIUMPH-1 results were substantial: −19.0%, −25.9%, and −28.3% of body weight at 80 weeks for the 4 mg, 9 mg, and 12 mg doses, versus −2.2% for placebo.
• Tolerability at the top dose was meaningful. About 1 in 9 participants on 12 mg stopped the drug because of side effects (11.3%, versus 4.9% on placebo).
• FDA has stated plainly that retatrutide cannot be used in compounding under federal law. Vials sold online as “research peptides” are unapproved drugs, and FDA has issued warning letters to companies selling them.
• Several highly effective FDA-approved medications exist right now. Waiting years for a drug that has not yet been submitted for review has a real cost.

What Is Retatrutide, and What Does “Triple Agonist” Mean?

Retatrutide is a single injectable molecule that activates three different hormone receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. An agonist is simply a molecule that switches a receptor on. A triple agonist switches on three.

That is one more target than anything currently on the market.

What each of the three receptors does

GLP-1 (glucagon-like peptide-1). The mechanism behind semaglutide (Wegovy, Ozempic) and one half of tirzepatide. Activating it slows stomach emptying, increases fullness, and reduces appetite signaling in the brain.

GIP (glucose-dependent insulinotropic polypeptide). The second target of tirzepatide (Zepbound, Mounjaro). GIP activity appears to add appetite and metabolic effects beyond GLP-1 alone, though the mechanism is still being worked out.

Glucagon. The genuinely new one. Glucagon is usually thought of as the hormone that raises blood sugar — which sounds like the opposite of what you’d want. But glucagon receptor activation also increases energy expenditure and promotes the breakdown of stored fat, particularly in the liver.

Why adding glucagon receptor activity is mechanistically different

Every FDA-approved GLP-1-based medication works primarily by reducing how much you eat. Adding glucagon receptor activity introduces a second lever — increasing how much energy the body burns — alongside the appetite effect. That combination is the leading explanation for why retatrutide’s weight-loss numbers exceed what’s been reported for single- and dual-agonists.

It is a plausible, well-supported mechanism. It is not a different category of drug, and it does not eliminate tradeoffs — glucagon receptor activity also raises questions about heart rate and glucose handling that regulators will examine closely during review.

What the Phase 3 TRIUMPH-1 Results Actually Showed

Eli Lilly reported topline results from TRIUMPH-1 on May 21, 2026. It was a Phase 3, randomized, double-blind, placebo-controlled trial of 2,339 adults with obesity or overweight without diabetes, randomized 1:1:1:1 across three doses and placebo, with lifestyle modification in all groups.

Average body weight reduction at 80 weeks (efficacy estimand):

At the 12 mg dose, 62.5% of participants lost at least 25% of their body weight, and 45.3% lost at least 30%.

An “efficacy estimand” estimates what happens in people who stay on the drug as intended. Lilly also reported a treatment-regimen estimand, which counts everyone regardless of whether they stopped: −25.0% at 12 mg versus −3.9% for placebo. Both are legitimate; the second is closer to what an average patient population experiences. Any article citing only the larger number is telling you half the story.

The 104-week extension

A pre-specified extension enrolled 532 participants with a starting BMI of 35 or higher who had completed 80 weeks without discontinuing or permanently reducing their dose. At 104 weeks, those on 12 mg titrated to their maximum tolerated dose had lost an average of 30.3% of body weight (−85.0 lb).

Two caveats matter: this was a selected group who had already tolerated the drug for 80 weeks, and it included only higher-BMI participants. It shows the effect is durable through two years in people who do well on it. It does not predict what an average person starting the drug would experience.

How this compares to approved medications

Retatrutide’s numbers are higher than those reported for approved agents. But these are separate trials in different populations, at different times, with different designs and durations. Cross-trial comparisons are not reliable evidence of superiority. Retatrutide has never been tested head-to-head against tirzepatide or high-dose semaglutide in a published trial. Until it is, the honest statement is that its results appear larger — not that it is proven better.

One more limitation worth naming: as of August 19, 2026, I could not locate a peer-reviewed primary publication of the TRIUMPH-1 outcomes. The trial program’s design has been published, but the results themselves currently rest on the manufacturer’s announcement. That is normal at this stage — and it means the full dataset has not yet been through independent peer review.

The Tolerability Data Deserves Equal Attention

This is the part most retatrutide coverage skips, and it is exactly what a patient needs in order to think clearly about the drug.

Adverse events at 12 mg versus placebo (TRIUMPH-1, 80 weeks):

Discontinuation because of adverse events: 11.3% at 12 mg versus 4.9% on placebo.

Read that last line carefully. Roughly one in nine people on the highest dose stopped the drug because of side effects — more than double the placebo rate. Discontinuation rose steadily with dose (4.1% at 4 mg, 6.9% at 9 mg, 11.3% at 12 mg), the same pattern seen across this drug class: more receptor activation produces more weight loss and more side effects.

That tradeoff is not a flaw in the drug. It is the central clinical decision. The 4 mg dose still produced a 19.0% average reduction with a discontinuation rate comparable to placebo. The “best” dose for a given person is the one that balances benefit against what they can actually live with — which is a conversation, not a number.

What is dysesthesia, and why does it keep showing up?

Dysesthesia is an abnormal, often unpleasant skin sensation — burning, tingling, prickling, unusual sensitivity to touch, or skin that feels painful without an obvious cause. It is not numbness, and it is not an allergic reaction.

It is worth explaining because it is appearing across the newer, higher-potency agents and most patients have never heard the word. The FDA-approved label for Wegovy (revised 06/2026) describes dysesthesia and related altered skin sensations occurring in clinical trials, and notes that incidence increased with increasing dose and blood drug levels — 22% at the 7.2 mg dose, 6% at 2.4 mg, and 0.3% on placebo. FDA notes it generally resolved on its own or with a dose reduction.

Retatrutide showed the same dose-related signal. If you are on any high-dose GLP-1-based medication and develop new burning or unusual skin sensations, report it to your physician rather than assuming it’s unrelated.

Where Retatrutide Stands With the FDA

As of August 19, 2026, retatrutide has not been submitted to the FDA, has not been approved, and cannot be prescribed.

Lilly stated on July 23, 2026 that it plans to submit a Biologics License Application (BLA) to FDA in the first quarter of 2027. That is a company plan, not an FDA action, and plans move — this one already has. Earlier in 2026 the company had indicated a possible submission by the end of 2026 before extending the timeline to complete manufacturing and quality documentation.

What still has to happen

1. Submission. The company files the application. Planned for Q1 2027.
2. Filing acceptance. FDA decides whether the application is complete enough to review.
3. Review. FDA evaluates efficacy, safety, and manufacturing quality.
4. Possible advisory committee. FDA may convene outside experts in a public meeting. Discretionary, not automatic.
5. Decision. Approval, a request for more information, or rejection.

I am not going to give you an approval date, because nobody credibly can. Drugs at this stage are still delayed, still receive requests for additional data, and occasionally still fail. Any site naming a specific availability month is guessing, and usually has something to sell you.

Retatrutide Sold Online: What the FDA Has Actually Said

Retatrutide is being sold on the internet right now — in vials, with dosing charts, sometimes with reconstitution videos — under labels reading “research peptide,” “for research purposes only,” or “not for human consumption.”

FDA’s position is not ambiguous. In its advisory on unapproved GLP-1 drugs used for weight loss (current as of June 15, 2026), FDA states verbatim:

“Retatrutide and cagrilintide cannot be used in compounding under federal law.”

FDA also states in the same advisory:

“FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption.'”

There is no legal pathway to a legitimate vial of retatrutide outside a clinical trial — not through a compounding pharmacy, not through a telehealth service, not through a peptide retailer. Lilly’s own statement is direct: retatrutide is legally available only through its clinical trials, and anything sold to consumers outside those trials is illegal.

The “research use only” label is not a legal workaround

It is a marketing device, and FDA treats it as one. In a warning letter issued March 31, 2026 to a peptide seller offering retatrutide, FDA wrote:

“Despite statements on your product labeling marketing your products for ‘Research Use Only,’ and ‘not intended for human consumption, medical use, or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”

FDA classified those products as unapproved new drugs. The label does not change what the product is. It shifts liability to the buyer.

FDA has separately established Import Alert 66-80, “Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances” (most recently revised August 13, 2026), allowing detention of GLP-1 active pharmaceutical ingredients from unverified sources — an acknowledgment that substantial volumes of this raw material are entering the country from unvetted facilities.

What you cannot know about an unregulated vial

When a vial arrives at a house in Savannah or Richmond Hill from an unregulated seller, here is what is genuinely unknowable:

• Identity. Whether the powder is retatrutide at all, a cheaper peptide, or a mixture.
• Purity. What else is in it. Synthesis byproducts and process impurities are invisible, and controlling for them is precisely what regulated manufacturing does.
• Concentration. How many milligrams are actually in the vial. Your dose depends entirely on that number being accurate, and you cannot check it.
• Sterility. Whether the product is free of bacteria and endotoxins. As FDA put it in that warning letter, injections “bypass some of the body’s key defenses against toxins and microorganisms.”
• Storage and shipping history. Peptides degrade with heat, and FDA has documented compounded GLP-1 products arriving warm or with inadequate ice packs. A vial that sat on a porch in a Coastal Georgia July is not the product that shipped.
• Dosing. Self-reconstituted products require the user to calculate a dose. FDA has flagged hospitalizations connected to dosing errors, including confusion between units and milligrams.

What FDA has documented so far

As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA notes these are likely undercounts, stating verbatim:

“Federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported.”

Those figures are for compounded versions of approved drugs, made by licensed pharmacies under some degree of oversight. Gray-market retatrutide sits further outside that system, with no reporting requirement at all — which means there is no counting mechanism, not that there is nothing to count.

And if something goes wrong

There is no manufacturer to notify, no lot number to trace, no recall mechanism, and no reporting pathway that connects back to anyone responsible. Your prescriber didn’t order it, so it may not be in your chart — and if you end up in an emergency department, the treating physician is working without knowing what you actually took or how much.

I am not trying to frighten anyone. People buying these products are usually motivated, informed, and frustrated — by cost, by a long wait, or by being told no. Those are real problems worth solving. This particular solution carries risks that cannot be measured or managed, and that is the honest medical assessment.

What to Do in the Meantime

The strongest practical argument against waiting for retatrutide is that the current options are genuinely good.

As of August 2026, the FDA-approved landscape for chronic weight management includes weekly injectable tirzepatide, weekly injectable semaglutide including a higher-dose 7.2 mg version approved in March 2026, two daily oral options approved within the past year, and several older non-GLP-1 medications that still work well for the right patient. Approved injectables have produced average reductions in roughly the 15–21% range in their pivotal trials, with the higher-dose semaglutide trial reporting more.

Obesity is a progressive condition. Blood pressure, blood sugar, joints, sleep apnea, and cardiovascular risk do not pause while a pipeline drug moves through review. If retatrutide is eventually approved — and neither the timing nor the outcome is guaranteed — that could still be years away for someone who could be treated now.

I am not telling anyone what to do, and the calculation isn’t the same for everyone. If you have tried the approved agents and genuinely could not tolerate them, waiting may be reasonable. But “waiting for the better one” deserves honest examination, because the cost of waiting is usually invisible while the benefit is speculative. Starting treatment now also forecloses nothing later — if retatrutide is approved, switching is a conversation you can have then.

Related: check whether you may be a candidate for medical weight management.

How to Follow Retatrutide’s Progress Credibly

If you want to track this without being marketed to:

• ClinicalTrials.gov — search “retatrutide” or the TRIUMPH-1 identifier NCT05929066. The federal trial registry shows enrollment status, endpoints, and completion dates.
• FDA.gov — approvals appear in Drugs@FDA and in FDA press announcements. If retatrutide is approved, it will be there first and it will be unambiguous.
• Lilly’s investor newsroom — where topline results and stated submission timelines are announced.
• Peer-reviewed journals — full TRIUMPH results will eventually be published, and that is where independent scrutiny happens.

Treat anything else with appropriate skepticism, particularly a site that reports approval news alongside a product for sale. If a page tells you retatrutide has been approved, cleared, or is “now available,” check Drugs@FDA before you believe it.

When to Talk to Your Doctor

Talk to a physician before doing anything with a product obtained outside the prescription system. If you have already used a research-labeled peptide, tell your doctor. You will not be lectured by anyone worth seeing, and it matters clinically — it changes how symptoms are interpreted and what tests make sense.

Routine reasons to schedule a visit:

• You’re on a GLP-1 and wondering whether to wait for something newer
• Side effects are affecting your quality of life or your ability to stay on treatment
• Weight loss has stalled and you want the plan reassessed
• New burning, tingling, or unusual skin sensitivity (possible dysesthesia)
• You’ve been considering an online peptide purchase and want a straight answer first

Seek urgent or emergency care for severe, persistent abdominal pain, especially radiating to the back and with vomiting (possible pancreatitis); signs of significant dehydration from persistent vomiting or diarrhea; signs of infection at an injection site — spreading redness, warmth, swelling, or fever; or any signs of a severe allergic reaction, including difficulty breathing, or swelling of the face, lips, or throat. Injection-site infection after using a non-sterile product is not a wait-and-see situation.

Scale Solutions & Coastal Georgia

The retatrutide question comes up often at Scale Solutions, usually in one of two forms: should I wait for it? or should I buy it?

Neither has a generic answer, which is why an ongoing relationship with a physician matters here more than for most topics. Whether waiting makes sense depends on your current treatment, how well it’s working, what you’ve already tried, your comorbidities, and how much untreated time you can afford. Whether an online vial is a risk worth taking depends on facts about the product that nobody can verify from a website.

A local practice can review your history, look at what stopped working and why, monitor labs and side effects over time, adjust doses rather than defaulting to the maximum, and tell you plainly when something new is worth switching to and when it isn’t. When retatrutide or another pipeline drug is approved, that same relationship is what turns the news into a real decision rather than a marketing message.

If you live in Savannah, Chatham County, Pooler, Richmond Hill, Hinesville, or anywhere in Coastal Georgia and you have questions about retatrutide, about a peptide product you’ve been offered, or about whether your current medication is still the right one — you’re welcome to reach out to Scale Solutions. Ask us the question before you order the vial. That conversation costs nothing and it is not a sales pitch.

Related: FDA-approved GLP-1 treatment options available now.

Related: how compounded products differ from FDA-approved medications.

Related: how we monitor patients on GLP-1 therapy.

Related: what happens when you stop a GLP-1.

Related: our editorial and sourcing standards.

Frequently Asked Questions

Is retatrutide FDA approved? No. As of August 19, 2026, retatrutide is investigational and has not been approved by the FDA or any regulatory agency. It cannot be legally prescribed in the United States.

When will retatrutide be available? No approval date exists. Lilly stated in July 2026 that it plans to submit an application to the FDA in the first quarter of 2027. FDA review takes additional time after submission, and approval is never guaranteed. Anyone naming a specific availability date is speculating.

Can a compounding pharmacy make retatrutide? No. FDA has stated that retatrutide and cagrilintide “cannot be used in compounding under federal law.” There is no legal compounded version.

Is retatrutide sold online the real thing? There is no way to know. Products sold as “research peptides” are not manufactured, tested, or shipped under FDA oversight, and their identity, purity, concentration, and sterility are unverifiable. FDA has issued warning letters to companies selling retatrutide under “research use only” labeling and classified those products as unapproved new drugs.

How much weight did people lose on retatrutide in Phase 3? In TRIUMPH-1, average reductions at 80 weeks were 19.0% at 4 mg, 25.9% at 9 mg, and 28.3% at 12 mg, versus 2.2% for placebo (efficacy estimand). A 104-week extension limited to higher-BMI participants who tolerated the drug through 80 weeks reached 30.3%.

Is retatrutide better than Zepbound or Wegovy? Its reported numbers are higher, but it has not been compared head-to-head against tirzepatide or high-dose semaglutide in a published trial. Comparing results across separate trials with different populations and designs is not reliable evidence of superiority.

How bad are the side effects? At 12 mg, nausea occurred in 42.4% of participants, diarrhea in 32.0%, constipation in 26.1%, and vomiting in 25.3%. About 11.3% discontinued because of adverse events versus 4.9% on placebo — roughly one in nine at the top dose. Lower doses were better tolerated and still produced substantial weight loss.

Should I stop my current medication and wait for retatrutide? That is a decision for you and your physician, not an article. What’s worth knowing: retatrutide has not yet been submitted for FDA review, effective approved options exist now, and untreated obesity continues to affect blood pressure, blood sugar, joints, and cardiovascular risk while you wait.

Conclusion

Retatrutide’s Phase 3 results are the most substantial weight-reduction data reported for an obesity medication so far, and its tolerability profile at the highest dose is meaningful enough that dose selection will be a real clinical conversation if and when it is approved. It has not been submitted to the FDA. It cannot be prescribed, and it cannot be compounded. What is sold online under that name is an unapproved drug of unverifiable identity, purity, concentration, and sterility — and FDA has said so directly.

If a website has offered you retatrutide, or you are weighing whether to keep waiting instead of starting treatment that’s available now, bring that question to Scale Solutions before you act on it. We will give you the current evidence, tell you honestly what is and isn’t known, and help you decide whether the right move is a change now or a plan to revisit it when the regulatory picture changes. Patients throughout Savannah and Coastal Georgia are welcome to contact us with exactly this kind of question.

MEDICAL SOURCES & FURTHER READING

1. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of June 15, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss — source for the statement that retatrutide and cagrilintide cannot be used in compounding, the “research purposes” labeling warning, the adverse event counts as of May 31, 2026, and the underreporting statement.

2. U.S. Food and Drug Administration. Warning Letter — Gram Peptides (CMS #721806). March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026 — source for FDA’s position on “Research Use Only” labeling of retatrutide products and their classification as unapproved new drugs.

3. U.S. Food and Drug Administration. Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances. Published August 13, 2026. https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html

4. U.S. Food and Drug Administration. FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients. September 5, 2025. https://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients

5. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss — source for all TRIUMPH-1 efficacy, estimand, adverse event, and discontinuation figures.

6. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional — source for the stated plan to submit a Biologics License Application to FDA in Q1 2027.

7. Eli Lilly and Company. What to know about retatrutide. Updated July 2026. https://www.lilly.com/news/stories/what-to-know-about-retatrutide — source for the manufacturer’s statement that retatrutide is legally available only through its clinical trials.

8. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026 Jan;28(1):83–93. DOI 10.1111/dom.70209. PMID 41090431. https://pubmed.ncbi.nlm.nih.gov/41090431/

9. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. DOI 10.1056/NEJMoa2301972. PMID 37366315. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 — source for the Phase 2 dose-response and mechanism background.

10. ClinicalTrials.gov. TRIUMPH-1 (NCT05929066) — A Study of Retatrutide in Participants With Obesity or Overweight. https://clinicaltrials.gov/study/NCT05929066

11. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection, Prescribing Information, revised 06/2026 — source for the dysesthesia labeling language and dose-related incidence figures. https://www.accessdata.fda.gov/scripts/cder/daf/

Scale Solutions editorial and sourcing standards: https://scale-solutions.com/editorial-policy/